Clinical Trials · NCT02941926
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 3,246
- Start date
- Nov 2016
- Locations
- 495 sites, 38 countries
- Primary endpoint
- Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core Phase